Trial Profile

Phase Ib/II Study of XmAb23104 (PD1 X ICOS) and XmAb22841 (CTLA-4 X LAG3) Combination in Metastatic Melanoma Refractory to Prior Immune Checkpoint Inhibitor Therapy with and Without CNS Disease

Status: Discontinued

Phase of Trial: Phase I

Latest Information Update: 01 Apr 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

26 Mar 2025 Status changed from active, no longer recruiting to discontinued.
06 Sep 2024 According to a Xencor media release, the company will host Research & Development Webcast and Conference call on monday, September 9, 2024, at 8:00 a.m. ET (5:00 a.m. PT), to provide updates on continued progress in dose escalation with first-in-class oncology programs.
21 Mar 2024 Sequential has been removed from study design, phase has been amended to phase 1 only and number of treatment arms has been changed to 3 from 5.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com